By Dean Seal
Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment.
The company said Thursday that the extended cooperative research and development agreement with the National Center for Advancing Translational Sciences is a boon for NES100, its product candidate for managing acute and chronic non-cancer pain.
The National Center for Advancing Translational Sciences is an institute of the National Institutes of Health, part of the U.S. Department of Health and Human Services.
The company's stock more than doubled to $1.21 in after hours trading after the extension was announced.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 21, 2024 16:41 ET (21:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。